Acrylamide-encapsulated glucose oxidase inhibits breast cancer cell viability
TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, vol.45, no.6, pp.811-816, 2020 (SCI-Expanded, Scopus, TRDizin)
- Publication Type: Article / Article
- Volume: 45 Issue: 6
- Publication Date: 2020
- Doi Number: 10.1515/tjb-2020-0247
- Journal Name: TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, TR DİZİN (ULAKBİM)
- Page Numbers: pp.811-816
- Keywords: biocompatibility, cancer therapy, glucose oxidase, MCF-7, single enzyme nanoparticle, starving-like therapy, therapeutic enzyme, NANOPARTICLES, ASPARAGINASE
- Dokuz Eylül University Affiliated: Yes
Abstract
Objectives: Cancer cells modulate metabolic pathways to ensure continuity of energy, macromolecules and redoxhomeostasis. Although these vulnerabilities are often targeted individually, targeting all with an enzyme may prove a novel approach. However, therapeutic enzymes are prone to proteolytic degradation and neutralizing antibodies leading to a reduced half-life and effectiveness. We hypothesized that glucose oxidase (GOX) enzyme that catalyzes oxidation of glucose and production of hydrogen peroxide, may hit all these targets by depleting glucose; crippling anabolic pathways and producing reactive oxygen species (ROS); unbalancing redox homeostasis.